Microbes and mood: innovative biomarker approaches in depression

• Published in: Trends in molecular medicine 2024-09
• Main Authors: Green, Miranda, Trivedi, Madhukar H., Foster, Jane A.
• Format: Article
• Language: English
• Subjects: bioinformatics; microbiome; precision medicine; short-chain fatty acids; translational; tryptophan metabolism
• ISSN: 1471-4914; 1471-499X; 1471-499X
• DOI: 10.1016/j.molmed.2024.09.002

Advances in human microbiome research have the potential to improve clinical outcome across biomedical sciences.Animal studies provide evidence that gut microbiota influences brain function and behavior.Clinical studies show the importance of the gut–brain signaling in depression.Microbiome-informed biomarkers have the potential to help us decipher the biological basis of clinical heterogeneity in depression.Recent innovations in bioinformatics and analytical approaches to study the microbiome will generate robust and reproducible biomarkers and molecular targets for precision medicine approaches and novel drug development. Although the field of psychiatry has made gains in biomarker discovery, our ability to change long-term outcomes remains inadequate. Matching individuals to the best treatment for them is a persistent clinical challenge. Moreover, the development of novel treatments has been hampered in part due to a limited understanding of the biological mechanisms underlying individual differences that contribute to clinical heterogeneity. The gut microbiome has become an area of intensive research in conditions ranging from metabolic disorders to cancer. Innovation in these spaces has led to translational breakthroughs, offering novel microbiome-informed approaches that may improve patient outcomes. In this review we examine how translational microbiome research is poised to advance biomarker discovery in mental health, with a focus on depression. Although the field of psychiatry has made gains in biomarker discovery, our ability to change long-term outcomes remains inadequate. Matching individuals to the best treatment for them is a persistent clinical challenge. Moreover, the development of novel treatments has been hampered in part due to a limited understanding of the biological mechanisms underlying individual differences that contribute to clinical heterogeneity. The gut microbiome has become an area of intensive research in conditions ranging from metabolic disorders to cancer. Innovation in these spaces has led to translational breakthroughs, offering novel microbiome-informed approaches that may improve patient outcomes. In this review we examine how translational microbiome research is poised to advance biomarker discovery in mental health, with a focus on depression.